Hot or Not, Stock Market Edition: 03/17/2026
Happy Tuesday. Here’s what’s hot and what’s not today, according to the Zen Ratings system:
- Hot: Gold royalty player Osisko Gold Royalties (OR) is gaining momentum; insurance heavyweight Allstate (ALL) looks poised to outperform
- Not: Biotech player BioNTech (BNTX) is feeling the frost; Business services provider Thomson Reuters (TRI) is losing steam
P.S. Speaking of hot, check out this video featuring 6 stocks under $35 you’ve probably never heard of…
A note from our sponsors...
Buffett's $114 Secret In 1943, a teenage Warren Buffett put $114 into a special type of account called "The 29% Account." Today, that single, $114 investment would be worth over $15 million. Your bank never told you about this. Click Here to See How It Works🔥 HOT: Property & Casualty Insurance giant Allstate (ALL) is demonstrating that even the beleaguered insurance industry is capable of making a comeback. After aggressively raising auto-insurance premiums over the past two years, Allstate is now seeing those increases flow through to earnings, driving a rebound in underwriting margins and overall profitability. The stock is modestly down in the past few months, but signs point to a turnaround led by solid fundamentals. With $67.7 billion in revenue and $10.2 billion in net income, Allstate's fundamentals remain rock-solid. The stock also just got an upgrade in our Zen Ratings from C (Hold) to B (Buy), placing it in the top 20% of stocks we track. Looking at the Component Grades for specific areas of strength, it earns an A Grade for AI and B Grades for Sentiment and Value. The bottom line? The combination of proven earnings power with a compelling valuation make it a compelling watch for investors seeking exposure to the insurance sector.
🥶 NOT: Biotech player BioNTech (BNTX) is losing steam after its pandemic-era highs. The reason is simple enough: The company faces the challenge of transitioning from its COVID-19 vaccine success to sustained growth in other areas. While BioNTech continues to invest in its pipeline of oncology and infectious disease candidates, investors are taking a more cautious stance as revenue from its mRNA COVID vaccines normalizes. And as you might expect, the stock has struggled to maintain momentum in recent months as the market reassesses its post-pandemic trajectory. This uncertainty is reflected in the Zen Rating: the stock was just downgraded to a D (Sell) rating, and ranks an unimpressive #388 out of the 469 stocks in the (F-rated) Biotech industry. (Looking for a better stock in the biotech/pharma sphere? Check out this video.) The stock shows additional weaknesses in the Component Grades — Ds for Growth, Safety, and Sentiment. The bottom line? While BNTX might still have a promising pipeline, until we see clearer catalysts from its non-COVID programs, investors might want to wait on the sidelines.
🔥 HOT: Gold royalty player Osisko Gold Royalties (OR) is up over 100% in the past year, but the move might not be over. Despite recent volatility in precious metals — with gold and silver prices pulling back amid dollar strength and Middle East tensions — OR's underlying fundamentals remain solid. The stock was just upgraded to a B (Buy) Zen Rating, which means it ranks in the top 20% of stocks we track based on a careful 115-factor fundamental analysis. It has some noteworthy and specific strengths as revealed by the Component Grades — above-average Bs for Momentum and Financials, indicating a company with a solid balance sheet that’s still on an upswing. All said? OR's combination of strong financial fundamentals, technical breakout potential, and positive analyst sentiment makes it an attractive play for investors looking to capitalize on gold royalty exposure with solid underlying metrics.
🥶 NOT: Specialty Business Services provider Thomson Reuters (TRI) has been under pressure, down significantly over recent months and trading well below its moving averages — a sign that momentum has stalled (a theory supported by its Component Grade of D for Momentum). The stock was just downgraded to an overall C (Hold) Zen Rating, putting it firmly in the middle of the pack with few standout points to make it a compelling buy — aside from Momentum, the other Component Grades are middling, and the only above-average mark the stock gets is a B for Safety. With weak momentum, middling ratings across key factors, and analyst caution, Thomson Reuters looks like a wait-and-see situation for now.
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.